Kaliumchlorid B. Braun

Potassium chloride, the active ingredient in Kaliumchlorid B. Braun, is a potassium salt presented as a sterile solution for injection for intravenous use. It restores extracellular potassium levels in patients with hypokalemia, counteracts potassium loss from diuretic therapy, and supports electrolyte balance during intravenous fluid administration.

GNH USA supplies Kaliumchlorid B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide, with distribution across EU and other regulated markets, ensuring product quality and regulatory compliance.

Kaliumchlorid B. Braun, a potassium salt electrolyte supplement, is used to correct potassium deficits in several clinical situations. - Hypokalemia: restores normal serum potassium concentrations, alleviating muscle weakness and cardiac arrhythmia risk. - Diuretic‑induced potassium loss: replenishes potassium lost during loop or thiazide diuretic therapy. - Intravenous fluid therapy: maintains potassium balance when patients receive large‑volume IV fluids.

Intravenous potassium chloride can be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: mild discomfort or burning at the infusion site. - Hyperkalemia: elevated serum potassium if administered excessively. - Nausea: transient feeling of queasiness. - Muscle twitching: mild, self‑limiting fasciculations.

Serious or Rare Side Effects: - Cardiac arrhythmia: life‑threatening rhythm disturbances. - Venous irritation or phlebitis: inflammation of the vein. - Severe hyperkalemia: marked elevation leading to muscle weakness or paralysis. - Anaphylactoid reaction: rare hypersensitivity with hypotension and rash.

Proper use of Kaliumchlorid B. Braun requires attention to several safety considerations to minimize risks. - Cardiac monitoring: observe ECG when rapid infusion or high doses are administered. - Renal function: assess kidney function before use, as impaired excretion can raise potassium levels. - Concomitant potassium‑sparing agents: avoid concurrent use with ACE inhibitors, ARBs, or spironolactone without monitoring. - Infusion rate: limit to ≤10 mEq per hour through a large peripheral vein or central line to reduce irritation. - Serum potassium monitoring: check levels before and during therapy to maintain target range. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Potassium chloride may interact with several medications, altering potassium balance or cardiac safety.

Major Interactions (Avoid): - ACE inhibitors, ARBs, or aldosterone antagonists: can cause dangerous hyperkalemia. - Digoxin: increased risk of digoxin toxicity when potassium is low or high. - NSAIDs: may reduce renal potassium excretion, raising serum levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypokalemia symptoms. - Insulin or glucose therapy: drives potassium into cells, potentially causing hypokalemia after correction. - Diuretics (loop or thiazide): may require higher potassium supplementation.